Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer

Stopped early · Phase 2

Conditions studied: Ovarian Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have refractory stage III or stage IV ovarian epithelial cancer.

Key facts

Study ID

NCT00006262

Run by

Northwestern University

Starts

2000-07-01

Expected to finish

2001-09-01

Last updated by the study team

2012-06-11

Who can join

Age: 21 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.